从不全性到完全性系统性红斑狼疮:预测性血清免疫标志物综述
系统性红斑狼疮(SLE)早期识别困难,部分患者表现为不全性SLE(iSLE)但并非均进展为SLE。本文综述SLE前期阶段免疫学变化,聚焦自身抗体、I型和II型干扰素及补体系统,并概述可用于日常临床实践的进展预测标志物。
要点
- iSLE患者需预测标志物识别高进展风险者以早期治疗。
- 综述聚焦自身抗体、I/II型干扰素及补体系统的预测价值。
- 部分标志物可能适用于日常临床实践进行风险分层。
核心结论
- 需要预测性生物标志物区分iSLE中高进展风险患者以允许早期治疗。
研究设计与样本
- 综述当前文献中SLE前期阶段免疫学变化,聚焦自身抗体、I型和II型干扰素及补体系统。
主要发现
- iSLE患者常出现提示SLE的临床症状和免疫异常但未满足分类标准。
- 并非所有iSLE患者均进展为SLE。
- 综述总结了SLE前期阶段自身抗体、I型和II型干扰素及补体系统的免疫学变化。
临床怎么用
- 概述可用于日常临床实践的进展至SLE的预测标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Systemic lupus erythematosus (SLE) is a complex and heterogeneous autoimmune disease. A main challenge faced by clinicians is early identification of SLE, frequently resulting in diagnostic delay. Timely treatment, however, is important to limit disease progression, and prevent organ damage and mortality. Often, patients present with clinical symptoms and immunologic abnormalities suggestive of SLE, while not meeting classification criteria yet. This is referred to as incomplete SLE (iSLE). However, not all these patients will develop SLE. Therefore, there is need for predictive biomarkers that can distinguish patients at high risk of developing SLE, in order to allow early treatment. This article reviews the current literature on immunological changes in patients with stages preceding SLE, focusing on autoantibodies, type-I and -II interferons, and the complement system. We also provide an overview of possible predictive markers for progression to SLE that are applicable in daily clinical practice.
引用
- Lambers WM, Westra J, Bootsma H, et al. From incomplete to complete systemic lupus erythematosus; A review of the predictive serological immune markers. Semin Arthritis Rheum. 2020. PMID: 33360229. doi:10.1016/j.semarthrit.2020.11.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。